Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Diffusion Pharmaceuticals Inc DFFN

Healthcare Biotechnology
Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine... see more

Recent & Breaking News (NDAQ:DFFN)

Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors

GlobeNewswire July 6, 2017

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial First Quarter 2017 Results

GlobeNewswire May 15, 2017

How These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma

PR Newswire April 28, 2017

18 Biggest Mid-Day Losers For Friday

Benzinga.com  April 7, 2017

Diffusion Pharmaceuticals Awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications

GlobeNewswire April 4, 2017

Mid-Afternoon Market Update: NovoCure Surges After Two-Year Survival Rate Increases For GBM Patients; Diffusion Pharma Shares Slide

Benzinga.com  April 3, 2017

Mid-Day Market Update: Dow Drops Over 100 Points; DryShips Shares Plummet

Benzinga.com  April 3, 2017

Diffusion Pharmaceuticals Announces Closing of Oversubscribed Private Placement

GlobeNewswire April 3, 2017

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports 2016 Financial Results

GlobeNewswire March 31, 2017

20 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  March 30, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  March 17, 2017

Diffusion Pharmaceuticals’ TSC Phase 1/2 Glioblastoma Multiforme Clinical Trial Results Published in February 2017 Edition of Journal of Neurosurgery

GlobeNewswire February 8, 2017

15 Biggest Mid-Day Losers For Thursday

Benzinga.com  January 19, 2017

15 Biggest Mid-Day Losers For Wednesday

Benzinga.com  January 11, 2017

15 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  January 10, 2017

20 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  January 10, 2017

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results

GlobeNewswire November 14, 2016

Diffusion Pharmaceuticals Announces Uplisting to NASDAQ Capital Market

GlobeNewswire November 8, 2016

Diffusion Pharmaceuticals Establishes Scientific Advisory Board

GlobeNewswire September 29, 2016

Diffusion Pharmaceuticals Successfully Completes Animal Toxicity Studies in Preparation for Phase 3 Pivotal Trial of TSC in New Diagnosed Glioblastoma Patients

GlobeNewswire September 19, 2016